PTS Diagnostics Presents at J.P. Morgan Healthcare & Biotech Showcase 2015
The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to and meet with peers, investors, and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather each year to do what is widely viewed as setting the tone for the coming year.
PTS Diagnostics was among best-in-class biotechnology and life science companies that presented to the more than 3,700 investors who attended the event. PTS Diagnostics’ products are sold in more 120 countries and its CardioChek analyzers have screened more than 120 million people worldwide.
“In 2014, PTS Diagnostics delivered revenue growth in excess of 40 percent resulting in a 5-year CAGR of greater than 25 percent. Our innovation pipeline will bring several exciting products to market in 2015,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Our core products test for important health indicators in the fastest growing global pointof-care testing segments (lipids and diabetes). We offer the only truly globally-available point-of-care solution for lipid testing with our CardioChek analyzers and test strips. In addition, sales of our A1CNow System surpassed 1 million tests in just 8 months since we acquired the A1C monitoring device.”
PTS Diagnostics products are manufactured in the United States, where it maintains facilities in the Midwest and Silicon Valley. The company’s 91 US and international patents and 86 pending patent applications place the company in a prime position to continue to work with the healthcare community to test more patients. Further, the company has entered into private label manufacturing agreements with major US pharmacies and retailers.
“PTS Diagnostics has built an expert medical device leadership team. Combined with the efforts of more than 3,000 medical distributor sales representative in the US alone, PTS Diagnostics is continuing to rapidly grow market share both domestically and abroad,” said Huffstodt.
PTS Diagnostics recently announced the launch of new technology for small-volume blood collection via its PTS Diagnostics™ Capillary Tubes, and has developed a wellness portal and health risk assessment software package to increase the quality of communication between patients and medical professionals.
“We continue to unveil new sources of growth such as pharma services, and the development of software such as the PTS Connect™ Wellness Portal, which will change the way screening participants will communicate with wellness programs,” concluded Huffstodt. “We look forward to the future as we continue to innovate point-of-care testing through our people, technology and service.”
PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.
PTS Diagnostics’ portfolio includes the following systems:
About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.
All trademarks used or mentioned in this release are protected by law.